The brain and drugs, their neurobiological mechanisms;El cerebro y las drogas, sus mecanismos neurobiológicos

Salud Mental

Volumn 33, Issue 5, 2010, Pages 451-456

  Díaz, Mónica Méndez ^a   Contreras, Alejandra E Ruiz ^a,b   Gómez, Berta Prieto ^a   Romano, Antonio ^a   Caynas, Seraid ^a   García, Oscar Prospéro ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Addictions comorbility; Drugs; Environment; Epigenesis; Genes; Punishment system; Rewarding system

Indexed keywords

EID: 84855239209     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. (2007, 2008). http://apps.who.int/classifications/apps/icd/icd10online/. Recuperado el 5 de febrero de 2010.
2. Martel P, Fantino M. Mesolimbic Dopaminergic System Activity as a function of food reward: A microdialysis study. Pharmacol Biochem Behav 1996;53:221-226.
3. Fiorino DF, Coury A, Phillips AG. Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. J Neurosci 1997;17:4849-4855.
4. Rosen RC, Bachmann GA Sexual well-being, happiness, and satisfaction in women: The case for a new conceptual paradigm. J Sex Marital Ther 2008;34:291-297.
5. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35:217-238.
6. Zombeck JA, Chen GT, Johnson ZV, Rosenberg DM, Craig AB et al. Neuroanatomical specificity of conditioned responses to cocaine versus food in mice. Physiol Behav 2008;93:637-50.
7. Escohotado A. Historia de las drogas 1 y 2. Madrid: Alianza Editorial; 1996.
8. Benítez F. En la tierra mágica del peyote. México: Editorial Era; 2006.
9. Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 2009;10:446-457.
10. Delgado MR, Jou RL, LeDoux JE, Phelps EA. Avoiding negative outcomes: Tracking the mechanisms of avoidance learning in humans during fear conditioning. Front Behav Neurosci 2009;3:1-9.
11. Ambroggi F, Ishikawa A, Fields HL, Nicola SM. Basolateral amygdala neurons facilitate reward-seeking behavior by exciting nucleus accumbens neurons. Neuron 2008;59:648-661.
12. Floresco SB, St Onge JR, Ghods-Sharifi S, Winstanley CA. Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making. Cog AffCogn Affect Behav Neurosci 2008;8:375-89.
13. Kosten TR, George TP. The neurobiology of opioid dependence: Implications for treatment. Sci Pract Perspect 2002;1:13-20.
14. Solomon RL, Corbit JD. An opponent-process theory of motivation. Am Econ Rev 1978;68:12-24.
15. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
16. Maldonado R, Valverde O, Barrendero F. Involvement of the endocanniboid system in drug addiction. Trends Neurosci 2006;29:225-232.
17. Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nat Rev Neurosci 2008;9:314-320.
18. Russo SJ, Mazei-Robinson MS, Ables JL, Nestler EJ. Neurotrophic factors and structural plasticity in addiction. Neuropharmacol 2009;56:73-82.
19. Koob GF, Le Moal M. Neurobiological mechanisms for opponent motivational processes in addiction. Phil Trans R Soc B 2008;363:3113-3123.
20. Julien RM, Advokat CL, Comaty JE. A primer of drug action. Onceava edición. Nueva York: Worth Publishers; 2008.
21. Soria EJ, Matías I, Cisneros M, Petrosinio S, Navarro L et tal. Pharmacological enhancement of the cannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-FOS expression in the hypothalamus. Brit J Pharmacol 2007;151:1109-1116.
22. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psych 2005;62:617-627.
23. Nair SG, Adams-Deutsch T, Epstein DH, Shaham Y. The neuropharmacology of relapse to food seeking: Methodology, main findings, and comparison with relapse to drug seeking. Prog Neurobiol 2009;89:18-45.
24. Swan GE, Lessov-Schlaggar CN, Bierut LJ, Shields AE, Bergen AW et al. Status of genetic studies of nicotine dependence. En: National Cancer Institute. Phenotypes and endophenotypes: Foundations for genetic studies of nicotine use and dependence. Tobacco Control Monograph No. 20 Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. NIH Publication No. 09-6366; 2009.
25. Ward RJ, Lallemand F, De Witte P. Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or 'binge drinking' alcohol abuse. Alcohol 2009;44:128-135.
26. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 2009;9:655-664.
27. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivty disorder: an update. Pharmacotherapy 2009;29:656-679.
28. Quinn D. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008;28(3 Supl 2):S62-66.
29. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety. Neuropharmacol 2009;57:608-618.
30. Vansickel AR, Stoops WW, Glaser PE, Rush CR. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacol 2007;193:305-313.
31. Yano M, Steiner H. Methylphenidate and cocaine: the same effects on gene regulation? Trends Pharmacol Sci 2007;28:588-596.